BioLineRx Q2 2026 Earnings Report

BioLineRx EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.15
• Beat/Miss: N/A
• One Year Ago EPS: N/A

BioLineRx Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BioLineRx Announcement Details

• Quarter: Q2 2026
• Date: 8/20/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

BioLineRx (NASDAQ:BLRX) (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist.

Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.